25 May 2012

ImmuPharma splits from US partner

21/10/2011 Robert Tyerman

Drug discoverer ImmuPharma (IMM) has ended a potentially lucrative development deal with US group Cephalon for its Lupuzor lupus treatment. The AIM-quoted company, which has received $45milion (£28.1 million) since 2008 under the arrangement out of a potential $500 million in milestone payments and royalties, says it requested a return of all rights to Lupuzor following Cephalon's takeover in May by Israel's Teva Pharmaceutical Industries, because Teva has a rival lupus treatment, Laquinimod. 

Spokesmen say ImmuPharma is negotiating with Cephalon about the future of a current round of clinical trials for Lupuzor initiated by Cephalon on lupus patients in the USA and Europe. Dimitri Dimitriou, ImmuPharma's entrepreneurial Chief executive officer, declares 'we are delighted to have Lupuzor back,' despite stockmarket concern over the loss of Cephalon's future milestone payments, and proclaims 'this paves the way for new options for the future of the company.'   

House broker Panmure Gordon argues ImmuPharma 'can now auction Lupuzor off for a second time' to a partner willing to accelerate its development. The broker still sees the company, which lost £2.5 million last year, losing £5.5 millon this time before making more than £18 million pre-tax in 2012 and reverting to losses the following year to the tune of almost £7 million and contends it is well enough capitalised to carry on for more than three years without a cash injection.

ImmuPharma shares, which surged from below 60p to more than 140p in 2009 on the original Cephalon deal, now trade at 73p, down 5.5p this morning on the loss of Cephalon's support. That is 13p below the price at which Dimitriou and chairman Richard Warr sold big chunks of their holdings in 2009 to enable institutional investor M&G to take a significant stake.

The shares are a punt on the company finding an attractive  new deal for Lupuzor. 

Tags: AIM market, Cephalon, Dimitri Dimitriou, Lupuzor

Sector: Pharmaceuticals & Biotechnology

Companies: ImmuPharma

Achieve impressive returns

Gain instant access to some of the best-performing and fastest growing companies in the small cap arena

Click here

Achieve impressive returns on the go

Gain instant access to some of the best-performing and fastest growing companies in the small cap arena. Sign up NOW!

Institutional Investors in AIM 2011 - New Report

This unique study analyses the shareholdings of companies listed on AIM, extracting trends including rankings of the value and number of their investments.
Please click here to order your copy of the report or call 0207 250 7056.

Coverage of AIM, techMARK and PLUS Markets

Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.

If you're interested in business tax updates visit our specialist tax guide website.

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Gulf starts at Sheikh Adi-2 25/05/2012

Iraq-focused oil explorer Gulf Keystone Petroleum (GKP) has begun drilling at the Sheikh Adi-2 well in the Sheikh Adi block.

Tags: Doing business in Iraq, Drilling on AIM, Oil on AIM

Sector: Oil & Gas Producers

Companies: Gulf Keystone Petroleum

Shell considers Cove 24/05/2012

Oil giant Shell is extending its offer period for Mozambique-focused Cove Energy (COV) after having its bid trumped by Thai government-owned PTT Exploration & Production.

Tags: Bid trumped, Doing business in Mozambique, Oil giants on AIM, Takeovers and bids

Sector: Oil & Gas Producers

Companies: Royal Dutch Shell 'A' , Cove Energy

Roxi reaches 1,360 metres 23/05/2012

Kazakhstan-focused Roxi Petroleum (RXP) has declared that its NK7 well in the Galaz aea has drilled to a depth of 1,360 metres.

Tags: AIM ventures, Doing business in Kazakhstan, Oil on AIM

Cluff Natural Resources joins AIM 22/05/2012

Steered by sector veteran Algy Cluff, North-Sea focused cash shell Cluff Natural Resources (CNR) has joined AIM.

Tags: Entrepreneurs on AIM, Gold mining, Oil and gas on AIM

Red Emperor exercises Shabeel 21/05/2012

Somalia-focused oil explorer Red Emperor Resources (RMP) has exercised its option to take part in the drilling of the Shabeel North well.

Tags: Business in the Puntland, Doing business in Somalia, Drilling for oil & gas, Oil on AIM

Sector: Oil & Gas Producers

Companies: Red Emperor Resources

Heritage happy in Iraq 18/05/2012

Oil concern Heritage Oil (HOIL) has reported its Miran West-3 well in Iraq could deliver 1,000 barrels per day of condensate.

Tags: Doing business in Iraq, Oil on the full list, Oil production, Target depth

Sector: Oil & Gas Producers

Companies: Heritage Oil

More News

Sectors